



COVID-19 DRUG SUMMARY: FAVIPIRAVIR ICU HOSPITAL KUALA LUMPUR (Revised 25 Jan 2021)

† Denotes discrepancies discussed with and consented by intensivist in charge and therefore, should only be applied at the current centre

Drug	Favipiravir 200mg tablet
Dose ^{1,2,3}	<ul style="list-style-type: none"> • Tab Favipiravir 1800mg (9 tabs) BD on Day 1 (total 3600mg in first 24 hours, space at least 4 hours between 1st & 2nd dose) then 800mg (4 tabs) BD Day 2 onwards • Total 5 days^{†3}
Administration ⁴	<ul style="list-style-type: none"> • Take with meals • NG tube feeding: Tablet can be crushed and dilute with warm water. Flush NG tube with water after serve.
Adverse effects ^{1,5,6}	<ul style="list-style-type: none"> • Hyperuricemia, elevated AST & ALT, diarrhea, skin eruption, reduction in neutrophil count
Precautions and Contraindications ^{1,5}	<ul style="list-style-type: none"> • Contraindicated in pregnancy and lactation • Renal impairment[†] <ul style="list-style-type: none"> - Avoid if CrCl < 30ml/min^{3,7} - ESRF on regular HD: no adjustment^{8,9} • Liver impairment[†] <ul style="list-style-type: none"> - Adjust if ALT and AST > 3X upper normal limit: 800mg (4 tabs) BD on Day 1, then 400mg (2 tabs) BD Day 2 onwards¹ • Total 5 days • Precaution use in gout patient
Drug-Drug interactions ^{1,5}	<ul style="list-style-type: none"> • Paracetamol: Favipiravir may ↑ level of paracetamol ; Limit maximum daily paracetamol dosage to 3 g^{10,11} • Pyrazinamide: ↑ uric acid level • Theophylline: ↑ favipiravir level

Prepared by: Tan Sin Yee & Andrew Yem

Reviewed by: Dr. Shanti R Deva

Date: 25 January 2021

References:

1. Faviflu®(favipiravir) product information leaflet
2. Joshi S, Parkar J, Ansari A et al. Role of favipiravir in the treatment of COVID-19. *Int J Infect Dis.* 2021 Jan;102:501-508.
3. Kementerian Kesehatan Malaysia. Clinical Management Of Confirmed Covid-19 Case In Adult. Updated 3 November 2020. Available from URL: <http://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm>. [Accessed on 14 Jan 2021]
4. The Japanese Association for Infectious Disease. Guidance of antiviral drug treatment for COVID-19 1st edition. Feb 2020. Available from URL: http://www.sukl.cz/file/92991_1_1. [Accessed on 9 Jan 2021]
5. Lexicomp Database Version 4.2.27. Hudson (OH): Lexicomp Inc.: 2020 [Updated 10 Dec 2020].
6. Favipiravir Observational Study Group, Fujita Health University. Favipiravir Observational Study Interim Report 2 (as of June 26, 2020). Available from URL: https://www.kansensho.or.jp/modules/en/index.php?content_id=3 [Accessed on 14 Jan 2021]
7. Marra F, Smolders EJ, El-Sherif O, et al. Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. *Drugs R D.* 2020;1-19.
8. Koshi E, Saito S, Okazaki M, et al. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019. *CEN Case Rep.* 2020 Sep 17: 1-6
9. Hirai D, Yamashita D, Seta K. Favipiravir for COVID-19 in a Patient on Hemodialysis. *Am J Kidney Dis.* 2021 Jan;77(1):153-154.
10. Zhao Y, Harmatz JS, Epstein CR, et al. Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. *Br J Clin Pharmacol.* 2015;80(5):1076-1085.
11. Assessment of Evidence for COVID-19-Related Treatments: Updated 12/17/2020. [Internet] Available from URL: <https://www.ashp.org/-/media/assets/pharmacy-practice/resource-centers/Coronavirus/docs/ASHP-COVID-19-Evidence-Table.ashx>